Brief: Biofrontera AG Announces Initiation Of Clinical Studies
16/11/2021 14:33
Nov 16 (Reuters) - Biofrontera AG B8FGn.DE :
* BIOFRONTERA AG ANNOUNCES INITIATION OF CLINICAL STUDIES
* BIOFRONTERA AG - ANNOUNCES THAT TWO CLINICAL STUDIES FOR
ITS
PRESCRIPTION DRUG AMELUZ(®) IN UNITED STATES ARE BEING STARTED
Source text for Eikon: ID:nGNX6TvZnk
Further company coverage: B8FGn.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera AG
See all newsBrief: Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million